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Compounds with specific cytotoxic activity in senescent cells, or senolytics, support the
causal involvement of senescence in aging and offer therapeutic interventions. Here we
report the identification of Cardiac Glycosides (CGs) as a family of compounds with senolytic
activity. CGs, by targeting the Na+/K+ATPase pump, cause a disbalanced electrochemical
gradient within the cell causing depolarization and acidification. Senescent cells present a
slightly depolarized plasma membrane and higher concentrations of H+, making them more
susceptible to the action of CGs. These vulnerabilities can be exploited for therapeutic
purposes as evidenced by the in vivo eradication of tumors xenografted in mice after
treatment with the combination of a senogenic and a senolytic drug. The senolytic effect of
CGs is also effective in the elimination of senescence-induced lung fibrosis. This experimental
approach allows the identification of compounds with senolytic activity that could potentially
be used to develop effective treatments against age-related diseases.
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S enescence is a crucial cellular response acting as a mor-phogenetic force during embryogenesis, contributing totissue remodeling and homeostasis in the adult, and pro-
tecting against cancer development1. Senescent cells are char-
acterized by a stable cell cycle arrest that is relevant for its tumor
suppressive function and by secreting a complex mixture of
soluble factors with immunomodulatory, extracellular matrix
remodeling and proliferative activity collectively known as the
SASP (senescence-associated secretory phenotype)2. This SASP
seems to act during development contributing to embryo mor-
phogenesis, and to provide signals for immune clearance of
senescence cells and to promote repair in adult damaged tissue3–
5. Excessive production of senescent cells due to chronic inducing
signals or a failure to remove them efficiently can lead to the
accumulation of damaged cells with impaired proliferative capa-
city and emitting signals with negative consequences1. Experi-
mental evidence points to this accumulation of senescent cells
with time as a cause of aging6,7. Senescent cells are prominent in
tissues from old individuals and in patients of premature aging
syndromes, at sites of age-related disease8. This build-up of
senescent cells in aged tissue could impair tissue function by the
incapacity to proliferate of the senescent cells and by the detri-
mental effect of SASP factors on neighboring cells9. Using
genetically modified mouse models to allow the elimination of
cells with induced expression of p16 (the product of gene
Cdkn2a), one of the main factors in senescence induction, sup-
ports this notion10,11. Removal of senescence cells improves the
healthspan of progeroid and old mice.
Oncogene induction in vitro and in vivo triggers a senescence
response that limits the proliferation of damaged cells effec-
tively preventing tumor development12. This powerful
tumor suppressive function of cell senescence has been envi-
sioned as a promising alternative to the use of cytotoxic
drugs13. In fact, evidence in mouse models of cancer and from
archived patient samples shows that senescence induction
contributes to treatment outcome14–16. However, the persis-
tence of senescent tumor cells secreting SASP factor with
potentially lethal activity represents a challenge for the devel-
opment of a pro-senescence therapy of cancer. Senescent tumor
cells have been suggested to promote relapse and metastatic
tumor growth17,18. In addition, chemo and radiotherapy-
induced senescence of normal healthy tissue could underlie
the adverse effects often associated with antitumor drugs19 and
radiation20–22.
Apart from the characteristic growth arrest and the SASP,
senescent cells induce resistance to cell death23,24. Contrary to
apoptosis, the senescence response generates damaged cells that
can remain in tissues for a prolonged period of time. Recently,
several compounds have been identified with selective cytotoxic
activity on senescent cells25–28. This so-called senolytic drugs
have the potential to remove specifically senescent cells in vitro
and in vivo, demonstrating a beneficial therapeutic effect against
aging and age-related diseases. Identifying the mechanisms of
apoptosis resistance in senescence cells might be helpful to
develop novel senolytic drugs. Alternatively, high-throughput
screening of chemical libraries might allow the unbiased identi-
fication of senolytic drugs whose action will rely on unidentified
vulnerabilities of senescent cells29.
With this later idea in mind, we develop a cell-based
screening strategy to identify senolytic compounds that we test
using a chemical repositioning library. Using this system, we
identify Cardiac Glycosides as a family of compounds showing
senolytic activity and demonstrate its potential use in combi-
nation with senogenic drugs as a potent antitumor strategy. In
addition, we describe the molecular basis for this senolytic
effect.
Results
High-throughput compound screening for senolytic activity.
We set up the conditions to screen for senolytic compounds using
as target cells a human lung adenocarcinoma cell line, A549
(Fig. 1a). As a proof-of-concept, we screened for compounds
showing senolytic activity in the Prestwick chemical library, a
collection of 1280 small molecules, mostly FDA/EMA approved
drugs, ideal for pharmacological repositioning. We derived clonal
GFP and RFP expressing versions of A549 by lentiviral trans-
duction and antibiotic selection, and induced senescence by
treatment with the chemotherapeutic drug Bleomycin (20 μM;
5 days), as previously described30. We plated mixed cultures of
proliferating A549-GFP and senescent A549-RFP cells (in a 1:3
proportion) in 384-well plates. One day later, we counted the
number of GFP and RFP cells using Operetta High-Content
Imaging System, added the compounds in the library (10 μM)
and repeated the counts 24 h later. For each plate we included
untreated wells as negative control or the well-known senolytic
drug, Navitoclax22 (1 μM) as positive control to calculate its
individual Z′ score. We calculated the percentage of change in the
cell populations before and after the treatments and obtained a
ratio that was used to select for potential hits. A total of 9
compounds showed the highest activity with a ratio of change in
the cell population above the threshold (average for the whole
population plus 3 standard deviations) (Fig. 1b). These initial hits
were further subjected to validation at two concentrations (10 and
1 μM) and were confronted with the results produced by our
positive control, Navitoclax. One of the compounds that passed
this confirmatory step was Proscillaridin A.
Proscillaridin A belongs to the Cardiac Glycosides (GCs)
family of compounds, derived from the foxglove plant (Digitalis
purpurea) whose therapeutic benefits were originally described
more than two centuries ago31, and that despite their toxicity are
used in the clinic for the treatment of congestive heart failure and
cardiac arrhythmias32. However, Proscillaridin A is not currently
used in the clinic and Digoxin is the most widely used CG for the
management of heart failure and in chronic atrial fibrillation33.
We decided to confront Proscillaridin A, Ouabain, one of the
most studied CGs, and Digoxin for their relative senolytic activity.
Using A549 tumor cells and primary human BJ fibroblasts
induced to senescence by Bleomycin treatment we confirmed that
all of them showed senolytic activity, with IC50 values in the
nanomolar range and with senolytic indexes ranging from 3.33
(Ouabain in A549 cells) to 301 (Proscillaridin in BJ cells)
(Fig. 1c). The cell killing activity of CGs was specific of the
senescence state, since quiescent cells showed lower sensitivity
than senescent cells (Supplementary Fig. 1a). Other tumor and
primary cell lines confirmed the universality of Digoxin senolytic
activity (Supplementary Fig. 1b, c). Furthermore, primary
chondrocytes from healthy and osteoarthritic donors were also
tested for Digoxin senolytic activity. We confirmed that
osteoarthritic chondrocytes are positive for senescence-
associated beta-galactosidase (SABG) and validated that Digoxin
treatment reduced their viability compared to cells from healthy
individuals (Supplementary Fig. 1d, e). In contrast, Digoxin did
not show any senolytic activity on mouse embryo fibroblasts due
to the well-known insensitivity of mouse cells to CGs (Supple-
mentary Fig. 1f)34. This senolytic effect was not observed
exclusively in cells induced to senescence by treatment with
Bleomycin. Using other senescence-inducing chemotherapeutic
drugs, Gemcitabine, Doxorubicine, Etoposide and Palbociclib, we
observed that in all cases Digoxin showed a similar senolytic
effect (Fig. 1d). To test whether Digoxin had senolytic activity on
cells induced to senescence by other senescence-inducing stimuli,
we overexpressed an oncogenic version of the HRAS gene on
human primary BJ fibroblasts or treated these same cells with
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H2O2. In both cases, Digoxin treatment led to the preferential
killing of the senescent cells (Fig. 1e).
In an independent manner, we set up another screening using a
melanoma cell line, SK-MEL-103, induced to senescence by
Palbociclib treatment (5 μM; 7 days). This time, we screened 480
compounds from the GPNCL library of natural compounds
(Greenpharma Natural Chemical Library) and 502 compounds
from the SCREEN-WELL® Natural Product library (ENZO).
Interestingly, all the six compounds that were found to be positive
in this screening belong to the CG family, namely Ouabain,
Bufalin, Cinobufagin, Peruvocide, Digitoxin, and Convallatoxin
(Fig. 1f). These compounds represent different sub-families
within the Cardiac Glycoside family, supporting the idea that
the observed senolytic activity is a general feature of CGs. Finally,
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using this same cell line and a library of 200 venoms and venom-
derived peptides and compounds from snakes, spiders, toads,
bees, centipedes, ants, octopus and lizards, we identified a group
of venoms showing senolytic activity, all of them derived from
toads (Supplementary Fig. 1g). Most of the species that were
positive for senolytic activity are well-known for containing
Bufadienolides, a subgroup of CGs35,36.
In summary, we have identified in three independent high-
throughput screenings several compounds from the CG family
with specific cytotoxic activity against senescent human primary
and cancer cells independently of the method used to induce
senescence.
Cardiac Glycosides kill senescent cells by apoptosis. To inves-
tigate the mechanism by which CGs were inducing cell death in
senescent cells we checked apoptosis induction. First, we analyzed
Annexin V staining as a surrogate marker of apoptotic cell death
using an Annexin V-FITC staining kit and flow cytometry ana-
lysis. Digoxin-induced senolysis clearly increased the percentage
of Annexin V positive A549 or BJ cells induced to senescence by
Bleomycin treatment (Fig. 2a). Similarly, we also observed
induction of active Caspase-3, another marker of apoptosis
(Fig. 2b). Finally, treatment with Z-VAD-FMK, an irreversible
pan caspase inhibitor, to block apoptosis resulted in protection
from the cell death induced by Digoxin (Fig. 2c). In contrast,
when we used inhibitors of other cell death pathways such as
ferroptosis and necroptosis we did not observe any protection
Supplementary Fig. 2). Thus, Digoxin provokes cell death mainly
by inducing apoptosis.
The Na+/K+ATPase is the senolytic target of CGs. CGs
mechanism of action consists mainly in the inhibition of the
Na+/K+ATPase pump, a plasma membrane enzyme that pumps
sodium out of the cell while pumping potassium into the cell
against their respective concentration gradients (Fig. 3a)37,38. The
inhibitory action is produced through binding to the alpha sub-
units of the Na+/K+ATPase pump, the product of the ATP1A1,
ATP1A2, ATP1A3 and ATP1A4 genes34. We reasoned that
overexpression of the ATP1A1 subunit could protect from the cell
death induced by Digoxin if this is part of its relevant senolytic
target. In addition, the mouse is known to express a Na+/K+
ATPase that is particularly resistant to the inhibitory action of
CGs34. Thus, overexpression of Atp1a1, the mouse ortholog of the
alpha 1 subunit of the Na+/K+ATPase, should show an even
stronger effect protecting senescent cells from Digoxin-induced
cell death. Lentiviral transduction of A549 cells with ATP1A1,
Atp1a1, or GFP as a negative control, showed that indeed the
overexpression of the alpha subunit of the Na+/K+ATPase
pump protects cells from the senolytic effect of Digoxin (Fig. 3b).
This protection was stronger when the mouse subunit was
expressed (Fig. 3b), even when similar levels of overexpression
were induced (Fig. 3c).
Interestingly however, the levels of expression of ATP1A1 are
very similar between proliferating and senescent cells, suggesting
that differential expression of ATP1A1 is not the cause behind the
higher sensitivity of senescent cells to Digoxin (Supplementary
Fig. 3a). To further confirm the involvement of ATP1A1 as the
relevant senolytic target of Digoxin, we knocked down this
subunit by siRNA transfection. However, low levels of ATP1A1
did not result in cell death (Supplementary Fig. 3b), suggesting
that perhaps other alpha subunits of the Na+/K+ATPase pump
might also be involved.
Inhibition of the Na+/K+ATPase pump by CGs have an
obvious effect on the relative intracellular concentration of Na+
and K+ions that can lead to the alteration of the plasma
membrane potential (Fig. 3a). Using a fluorescent probe (DiBAC4
(3)), we measured plasma membrane potential in proliferative
and senescent cells, treated or not with Digoxin. Senescent cells
showed a slight but significant increase in the fluorescent signal of
DiBAC4(3) compared with proliferating cells, an indication of a
partially depolarized plasma membrane in senescent cells
(Fig. 3d). This signal was further increased when senescent cells
were treated with Digoxin, a clear indication of the depolarizing
effect of Digoxin on senescent cells (Fig. 3d). To alleviate the
depolarization of the plasma membrane caused by the altered
ratio of Na+/K+, we decided to increase the concentration of K+
in the culture medium by adding KCl. Addition of KCl to the
culture medium recovered the normal polarization of the plasma
membrane as expected (Fig. 3d) while at the same time rescued
the senolytic cell death induced by Digoxin (Fig. 3e). In turn,
further increasing the concentration of Digoxin overcame the
protective effect of KCl (Fig. 3e). These results suggest that
depolarization of the plasma membrane by CGs could, at least in
part, explain their senolytic effect.
The increased concentration of sodium as a result of the Na+/
K+ATPase pump inhibition by CGs can result in the blockade of
the Na+/Ca2+ Exchanger (Supplementary Fig. 3c) and the Na+/
H+ Exchanger (Fig. 3a) due to the high intracellular concentra-
tion of Na+39,40. As a consequence, the levels of intracellular
Ca2+ and H+ could increase and trigger cell death. We decided
to measure intracellular Ca2+ levels using a fluorescent probe,
Calcium-6. Senescent cells showed a higher concentration of
intracellular Ca2+ compared to proliferating cells, and Digoxin
treatment increased even further this high level of Ca2+ in
senescent cells but not in proliferating cells (Supplementary
Fig. 3d). To test whether the raise in intracellular Ca2+ could be
behind the senolytic effect of Digoxin we treated proliferating and
senescence cells with a Ca2+ chelator, BAPTA-AM. Senescent
cells treated with Digoxin showed cell death independently of the
presence or not of BAPTA-AM, suggesting that intracellular Ca2
+sequestration does not have a protective effect against Digoxin-
induced senolysis (Supplementary Fig. 3e). On the other hand, to
measure the intracellular concentration of H+ we used a
fluorescent probe, pHrodo Green AM, that turns from weakly
to strongly fluorescent as the pH drops. Senescent cells showed a
Fig. 1 High-throughput screenings of senolytic compounds. a Schematic diagram of the experimental system used to screen compounds for potential
senolytic activity. b Scatter plot representing the normalized senolytic activity obtained with each compound present in the Prestwick Chemical Library.
Proscillaridin A value highlighted in red. c IC50 curves obtained with increasing concentrations of Proscillaridin A, Ouabain and Digoxin (from left to right)
in A549 tumor cells (upper panels) and BJ primary fibroblasts (bottom panels). Actual IC50 values and Senolytic Indexes (SI) are also shown for each
condition. d Relative cell viability (%) after Digoxin or vehicle treatment of A549 cells rendered senescent by different chemotherapeutic reagents (Bleo:
Bleomycin; Gem: Gemcitabine; Doxo: Doxorubicin; Eto: Etoposide; and Palbo: Palbociclib). n= 3 independent experiments. Statistical significance was
assessed by the two-tailed Student's t-test: ***p < 0.001. e IC50 curves of BJ primary fibroblasts induced to senescence by oncogenic RAS overexpression
(left panel) or H2O2 treatment (right panel) treated with increasing concentrations of Digoxin. f IC50 curves of SK-MEL-103 melanoma cells induced to
senescence by Palbociclib and treated with increasing concentrations of the indicated CGs identified on a screening for senolytic activities present in
compounds obtained from plant extracts. Data correspond to the average ± s.d. Source data for these experiments are provided as a Source Data file
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strong fluorescent signal compared to proliferating cells even in
the absence of Digoxin, but CG treatment caused an even further
increase in the fluorescence signal shortly (6 h) after treatment
(Fig. 3f), indicating a decrease in pH before senescent cells
undergo cell death. A prediction from this result is that
pharmacological inhibition of the NHE, using for example
Amiloride, should phenocopy the effect of Digoxin on senescent
cells. We treated proliferative and senescent cells with increasing
concentrations of Amiloride or left the cells untreated and
measured cell viability. Senescent cells were significantly more
affected and showed reduced viability, mimicking Digoxin
senolytic action (Fig. 3g). Conversely, increasing NHE activity
should have protective effect against the senolytic action of
Digoxin. To test this possibility, we overexpressed NHE1
(encoded by the gene SLC9A1) in proliferating and senescent
cells and treated the cell cultures with Digoxin. While proliferat-
ing and senescent cells showed similar levels of overexpression of
SLC9A1 (Fig. 3h), senescent cells treated with Digoxin were more
protected by SLC9A1 than the control (Fig. 3i).
Taken together, our data point to the alpha subunit of the Na
+/K+ATPase pump as the relevant target in Digoxin-induced
senolysis. Digoxin, by inhibiting this Na+/H+ Exchanger causes
an imbalance in the cellular concentrations of sodium and
potassium that results in the loss of membrane potential and
acidification of the cell. This effect is particularly detrimental in
senescent cells that already show depolarization of their plasma
membranes and high concentration of H+ in resting conditions.
Digoxin cooperates with senogenics in tumor regression. One
of the settings in which administration of a senolytic drug could
Fig. 2 CGs kill senescent cells by inducing apoptosis. a Annexin V positive cells (%) in proliferating (Pro, in green) and senescence (Sen, in red) A549 cells
(left panel) or primary BJ fibroblasts (right panel) after Digoxin treatment. b Active Caspase-3 positive cells (%) in proliferating (Pro, in green) and
senescence (Sen, in red) A549 cells (left panel) or primary BJ fibroblasts (right panel) after Digoxin treatment. c Relative cell viability (%) of proliferative
(Pro) or senescence (Sen) A549 cells treated with pan caspase inhibitor Z-VAD-FMK (ZVF), Digoxin (Dig) or the combination, as indicated. n= 3
independent experiments. All data correspond to the average ± s.d. Statistical significance was assessed by the two-tailed Student's t-test: ***p < 0.001;
**p < 0.01. Source data for these experiments are provided as a Source Data file
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have a clear beneficial effect is chemotherapy of cancer. Irrever-
sibly arresting tumor cells with a senescence-inducing drug
combined with inducing cell death with a senolytic compound
could potentially prove superior than the classical antitumor
chemotherapy. Our screenings for senolytic compounds were all
based on senescent tumor cells, both lung adenocarcinoma A549
and melanoma SK-MEL-103. To address whether CGs could have
antitumor activity by providing senolysis to a senescence-
inducing drug we injected subcutaneously A549 cells stably
expressing luciferase into immunodeficient nude mice, we let the
cells form tumors and, once they were detectable, we started a
treatment regime. For this, we administered Gemcitabine (25 mg/
kg, IP) or Digoxin (2 mg/kg, IP) alone, or the combination of
Gemcitabine plus Digoxin, and followed tumor progression by
measuring tumor volume and luciferase expression, twice weekly
(Fig. 4a). Both, Gemcitabine and Digoxin alone had a slight
Fig. 3 Mechanism of action of Digoxin-induced senolysis. a Diagram showing the activity of Digoxin. b Relative cell viability (%) of proliferative (green) or
senescence (red) A549 cells overexpressing human or mouse ATP1A1 or Atp1a1, respectively, and treated with Digoxin or Navitoclax. Statistical analysis
with Anova with Tuckey test: ***p < 0.001; *p < 0.05; c and mRNA expression (relative to GAPDH) of ATP1A1 (left) and Atp1a1 (right). n= 3 independent
experiments for both d Membrane potential determination of proliferative (green) or senescence (red) A549 cells treated with Digoxin and KCl, using
fluorescent probe DiBAC4(3). n= 10 biologically independent samples. Statistical significance by two-tailed Student's t-test: **p < 0.01; *p < 0.05. e
Relative cell viability (%) of proliferative (green) or senescence (red) A549 cells treated with Digoxin and KCl. n= 7 biologically independent samples.
Statistical analysis with Anova with Tuckey test: **p < 0.01. f Determination of the relative intracellular H+concentration in proliferative (green) or
senescence (red) A549 cells treated or not with Digoxin. n= 4 biologically independent samples. Statistical significance by two-tailed Student's t-test:
***p < 0.001. g Relative cell viability (%) of proliferative (green) or senescence (red) A549 cells treated or not with Amiloride. n= 3 biologically
independent samples. Statistical significance by two-tailed Student's t-test: ***p < 0.001. h Relative mRNA expression of SLC9A1 in proliferative (green) or
senescence (red) A549 cells overexpressing or not SLC9A1 as indicated. n= 3 biologically independent samples. Statistical significance by two-tailed
Student's t-test: **p < 0.01; *p < 0.05. i Relative cell viability (%) of proliferative (green) or senescence (red) A549 cells treated with Digoxin and
exogenously expressing SLC9A1 or GFP. n= 3 independent experiments. Statistical significance by two-tailed Student's t-test: **p < 0.01; n.s. not significant.
All data correspond to the average ± s.d. Source data for these experiments are provided as a Source Data file
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antitumor effect as shown by the reduced growth of the tumor
cells compared to the control animals (Fig. 4b, c). Interestingly,
the combination of Gemcitabine and Digoxin showed a robust
antitumor effect with a dramatic drop on tumor volume and
luciferase signal along the treatment period, with most of the
tumors actually disappearing after three weeks of treatment
(Supplementary Fig. 4a). Immunohistochemical analysis of the
treated tumors showed how Gemcitabine induces a robust
senescent response in the tumor as observed from the positive
senescence-associated beta-galactosidase (SABG) staining, the
loss of proliferation marker Ki67, and the expression of cell cycle
inhibitor p21 (Fig. 4d, e), all of them markers of cell senescence41.
Combination of Gemcitabine with Digoxin resulted in extremely
reduced tumors that were mainly composed of macrophages and
giant multinucleated immune cells surrounding a few SABG and
p21 positive, non-proliferating CK AE1/AE3 positive tumor cells
(Fig. 4d and Supplementary Fig. 4b). We also stained these
samples for active Caspase-3 and only observed very few positive
tumor cells undergoing apoptosis in the combination Gemcita-
bine plus Digoxin (Supplementary Fig. 4c, d).
To further prove the contribution of the senolytic activity
provided by Digoxin to the control of tumor growth we decided
to use a patient derived xenograft obtained from a breast tumor
patient (PDX375). This PDX was first characterized in vitro to
Fig. 4 Senolytic activity of Digoxin on xenografts. a Diagram showing the experimental plan to test the effect of administrating Gemcitabine, Digoxin or the
combination of both (Gem+Dig) in the growth of A549 cells expressing luciferase (A549-Luc) as subcutaneous tumors in nude mice. b Tumor volume
(mm3) progression with time after intraperitoneal injection of Gemcitabine (n= 12), Digoxin (n= 8) or the combination of both (Gem+Dig) (n= 12), or
vehicle (n= 4) as negative control as indicated. Statistical analysis was performed with Anova with Tuckey test: ***p < 0.001; **p < 0.01. c Tumor growth
determined by measuring normalized total flux of luminescence as detected by IVIS with the same groups of animals. Statistical analysis was performed
with Anova with Tuckey test: ***p < 0.001. d Representative images of SABG staining (upper panels) and immunohistochemical analysis of p21 (middle
panels) and Ki67 (bottom panels) in tumors obtained after injection of A549 cells in nude mice and treated with Gemcitabine, Gemcitabine plus Digoxin
(Gem+Dig), or control group (scale bar= 50 μm). e Quantifications of stainings shown in (d). n= 3 biologically independent samples. Statistical
significance was assessed by the two-tailed Student's t-test: ***p < 0.001; **p < 0.01; *p < 0.05. All data correspond to the average ± s.d. Source data for
these experiments are provided as a Source Data file
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test its response to the chemotherapy agent Doxorubicin. Staining
with SABG showed a clear induction of cell senescence and a
decreased number of cells when Doxorubicin was used but not
when cells were treated with Digoxin (Fig. 5a). In addition, we
transduced the tumor cells with reporter constructs for the
expression of CDKN1A (coding for p21) and IL6, both considered
markers of senescence41. Treatment with Doxorubicin caused a
clear induction of the reporters with some cells staining positive
for both markers, indicative of senescence (Fig. 5b, c). When we
treated the cells with Doxorubicin or Digoxin alone the viability
was slightly reduced, while the combination of Doxorubicin and
Digoxin resulted in a pronounced decrease in survival (Fig. 5d).
Next, we injected PDX375 in nude mice and treated the animals
with either compound alone or the combination, and we
determined tumor growth. Doxorubicin treatment was performed
at two different concentrations. When we treated mice with a
lower concentration (2 mg/kg), unable to induce senescence,
Digoxin did not show any collaborative effect (Fig. 5e). In
contrast, mice treated at a senescence-inducing concentration of
Doxorubicin (10 mg/kg) showed a significant reduction in tumor
volume when treated together with Digoxin (Fig. 5f). In these
models we treated human cancer cells implanted into immuno-
deficient mice. Unfortunately, the known insensitivity of rodents
to CGs34 precludes the possibility of using immunocompetent
mouse models of cancer development.
In summary, we have shown that Digoxin has antitumor
properties when combined with different senogenic chemother-
apeutic agents using two in vivo mouse models.
Digoxin is senolytic in lung fibrosis. Next, we wanted to test the
senolytic effect of Digoxin using another in vivo model of a non-
tumor related disease. For this, we established a mouse model of
lung fibrosis induced by intratracheal administration of senescent
Fig. 5 Senolytic activity of Digoxin on human PDX. a In vitro SABG staining of PDX375 in control, Doxorubicin, Digoxin and Doxorubicin plus Digoxin
(Dox+Dig) treated cells (scale bar= 100 μm). b Representative immunofluorescent images of PDX375 cells transduced with lentiviral reporter constructs
for the expression of p21 (in green) and IL6 (in red) in control condition or after Doxorubicin treatment. DAPI (in blue) was used to stained nuclei (scale
bar= 100 μm). c Quantification (fold change) of double positive p21/IL6 cells in control, or Doxorubicin (Doxo), Digoxin (Dig), or Doxorubicin plus Digoxin
(D+D) treatment (n= 3 biologically independent samples). d In vitro cell viability (relative to control) of PDX375 cells treated with Doxorubicin (Doxo),
Digoxin (Dig), or the combination (D+D) (n= 3 biologically independent samples). e In vivo growth (tumor volume) of PDX375 subcutaneously injected
into nude mice and treated with Doxorubicin (Doxo: 2 mg/kg; n= 6), Digoxin (Dig: 2 mg/kg; n= 6), the combination (D+D; n= 5), or vehicle (Control;
n= 5). f Same in vivo growth analysis in mice treated with Doxorubicin (Doxo: 10mg/kg; n= 8), Digoxin (Dig: 2 mg/kg; n= 8), the combination (D+D;
n= 6), or vehicle (Control; n= 8). Statistical significance was assessed by the two-tailed Student's t-test: ***p < 0.001; **p < 0.01; *p < 0.05. All data
correspond to the average ± s.d. Source data for these experiments are provided as a Source Data file
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human cells. Normal proliferating or gamma-irradiated (g-IR)
senescent human fibroblasts IMR90 were delivered into the lungs
of immunodeficient mice (Fig. 6a, b). Cell death analysis of
in vitro treatment with Digoxin of proliferating and g-IR IMR90
confirmed once again the senolytic effect of the CG (Fig. 6c).
Three weeks after intratracheal instillation, these animals were
subjected to Digoxin or vehicle treatment for ten days and their
lungs were removed and analyzed. First, we measured the
expression levels of CDKN2A (coding for p16INK4a) a typical
marker of primary fibroblast senescence42. Lungs from animals
injected with g-IR IMR90 showed high levels of this human gene
but not of the mouse ortholog, Cdkn2a, indicative of the presence
of senescent human cells in the mouse lungs (Fig. 6d). Similarly,
human CDKN1A (coding for p21) was also detected in the lungs
of mice receiving senescent human cells (Supplementary Fig. 5a).
Treatment with Digoxin caused a significant reduction in
CDKN2A expression levels and of CDKN1A (although not
reaching statistical significance for this gene), suggesting that
Digoxin caused the clearance of the human senescent cells
(Fig. 6d and Supplementary Fig. 5a). Finally, we stained the lungs
with Masson Trichrome, a well-established marker of fibrosis.
Lungs from animals injected with senescent g-IR IMR90 and
treated with vehicle stained positive, indicative of fibrosis, while
those treated with Digoxin had a reduced score of fibrosis (Fig. 6e,
f). In addition, we determined hydroxyproline content in lungs as
a measure of fibrosis and found that animals receiving senescent
g-IR IMR90 cells had a significantly higher level of this marker
compared to the ones injected with proliferating cells (Supple-
mentary Fig. 5b). In line with our results using Masson Tri-
chrome staining, mice treated with Digoxin showed a tendency to
have reduced levels of hydroxyproline (Supplementary Fig. 5b).
These results show the potential senolytic effect exerted by
Digoxin in vivo using a model of a disease, other than cancer,
caused by the accumulation of senescent cells.
Discussion
In recent years, the field of cell senescence has experienced a
significant expansion in part due to robust in vivo proof of the
causative involvement of senescent cells in aging and in particular
age-related diseases10,11. One of the elements providing a decisive
Fig. 6 Senolytic activity of Digoxin in lung fibrosis. a Schematic diagram of the experimental system to induce lung fibrosis in mice by intratracheal
instillation of proliferative or senescent gamma-irradiated IMR90 cells. b In vitro SABG staining of control or gamma-irradiated (g-IR) IMR90 cells (scale
bar= 100 μm). c In vitro analysis of cell death in control or (g-IR) IMR90 cells treated or not with Digoxin (Dig). Black bars represent the % of DiOC6(3)
low and grey bars represent Hoechst 33342 positive cells. n= 3 independent experiments. d Relative expression of the mRNA coding for CDKN2A (left
panel) or Cdkn2a (right panel) in lung cell extracts from mice injected with control proliferative (green) or gamma-irradiated (g-IR, red) IMR90 cells, and
treated or not with Digoxin, as indicated. n= 5 independent experiments. e Representative images of lung sections stained with Masson Trichrome from
mice injected with gamma-irradiated IMR90 cells and treated (bottom panel) or not (upper panel) with Digoxin (scale bar= 100 μm). f Ashcroft score of
Masson Trichrome staining in sections from mice injected with control proliferative or gamma-irradiated (g-IR) IMR90 cells, treated or not with Digoxin
(+Dig). n= 5 independent experiments. Statistical significance was assessed by the two-tailed Student's t-test: ***p < 0.001; **p < 0.01; *p < 0.05. Data
correspond to the average ± s.d. Source data for these experiments are provided as a Source Data file
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support for this recognition is the identification of senolytics,
small molecules with selective cytotoxic activity on senescent
cells43. Senolytics represent powerful tools to unequivocally
demonstrate the involvement of senescence cells in diseases
characterized by their accumulation44. At the same time, they
hold the promise of novel and effective treatments against age-
related diseases27,45,46.
The use of cellular senescence as a therapeutic tool was pio-
neered by efforts trying to use it as an antitumor strategy given
the powerful tumor suppressive function of this response13.
However, the prospect of letting senescent cancer cells hanging
around in the organism represents a potential threat of devel-
oping a secondary tumor with increased aggressiveness. The
identification and description of the complex secretory phenotype
characteristic of senescent cells known as SASP, with potential
tumor promoting activities, raised even more suspicion about the
possible harmful consequences of inducing senescence in tumor
cells18. In our view, combining senogenic and senolytic com-
pounds could have a synergistic antitumor effect that could prove
very effective in cancer treatment47. With these ideas in mind we
decided to search for new senolytic compounds that could offer
us the possibility of identifying vulnerabilities in senescent cells
and could provide us with novel therapeutic tools against age-
related diseases and in particular, cancer.
Cell-based phenotypic screening of chemical libraries repre-
sents a powerful tool to identify new potential drugs48. We
designed a robust screening platform for senolytic compounds
and tested it using a chemical library of approved drugs. As a
result of this screening we identified a compound, Proscillaridin
A, a drug belonging to the Cardiac Glycoside family. Interest-
ingly, two additional screenings using a library of compounds
derived from plant extracts and a collection of venoms, also
identified hits belonging to this same CGs family of compounds.
Digoxin, one of these CGs, is a commonly used drug for atrial
fibrillation and heart failure and in our hands showed a powerful
senolytic activity. Even though the therapeutic window for
Digoxin is quite narrow, this is a drug that has been successfully
used for decades. We can benefit from our knowledge on how to
administer the drug and how to follow and assess the patients,
and we have even developed effective blocking monoclonal
antibodies to revert possible drug overdoses49. Our experiments
show that at least for some particular cell types and senescence
inducers, the doses needed to achieve the senolytic effect fall
within the therapeutic range. This might not be the case for all the
cell types and an individual assessment will have to be done to
develop potential particular therapies.
Even though our screenings were based on the use of human
cancer cells, A549 and SK-MEL-103, induced to senescence either
by Bleomycin or Palbociclib, we showed that the use of other
chemotherapeutic drugs to induce senescence also allows seno-
lysis by Digoxin. In addition, primary BJ fibroblasts induced to
senescence by Bleomycin, expression of an oncogene, or damaged
by oxidative stress were also more sensitive to the cytotoxic effect
of Digoxin than their proliferative counterparts. We have also
expanded these observations to other tumor and primary cells. In
addition, similar results have been obtained by another group
performing independently cell-based screenings and using other
unrelated chemical libraries, further reinforcing the reproduci-
bility of our findings50.
CGs are known to exert their action primarily by binding to the
alpha subunit of the Na+/K+ATPase pump and inhibiting the
intake of K+ coupled with the release of Na+out of the cell34.
This inhibition initiates a cascade of events that results in dis-
torted electrochemical gradients involving several ions within the
cell. We confirmed the depolarization caused by Digoxin and
found that senescent cells show a slight depolarized plasma
membrane that puts these cells closer to a level of depolarization
that can trigger cell death when treated with Digoxin. Incubation
of senescent cells with KCl was sufficient to protect these cells
from senolysis induced by Digoxin and overexpression of the
alpha 1 subunit of the Na+/K+ATPase also partially rescued cell
death, proving the relevance of the known CG target on this
effect. The increased levels of Na+within the cell can result in the
blockade of the Na+/H+Exchanger, causing an increase in the
H+concentration. Indeed, the high concentration of H+seems to
be involved in Digoxin senolytic effect. Amiloride-mediated
inhibition of NHE phenocopied the effect of Digoxin, while
overexpression of NHE1 protected senescent cells from senolysis.
Interestingly, the levels of H+in senescent cells were already
higher than in proliferating cells and Digoxin further increased
this concentration.
As already mentioned above, we support the possibility of
developing a two-punch strategy against cancer based on cellular
senescence by combining senogenic and senolytic drugs. Since we
based our screening on the use of human cancer cells induced to
senescence by chemotherapeutic drugs, we decided to test the
effectiveness at controlling tumor growth of our candidate
senolytic, Digoxin. For this, we used xenografted A549 cells or a
breast cancer PDX treated with senogenic compounds Gemcita-
bine or Doxorubicin, respectively. Mice were treated with the
senogenics alone or in combination with Digoxin. Compared to
the weak antitumor effect obtained with each compound alone,
the combination of Gemcitabine or Doxorubicin plus Digoxin
proved to be synergistic and efficient at reducing the growth of
the cancer cells in vivo and even inducing complete regression of
tumors. To extend the range of potential applications of CGs as
senolytics, we tested a mouse model of lung fibrosis triggered by
administration of senescent human fibroblasts directly into the
lung. In this system, Digoxin preferentially induced cell death of
senescent cells and reduced the extend of the fibrosis.
In summary, we have identified Cardiac Glycosides as senolytic
compounds with robust activity both in vitro and in vivo, and
effective against tumor and primary cells. Depolarization and
high H+concentrations in senescence cells represent a vulner-
ability that can be exploited for therapy. Cardiac Glycosides, by
inducing a disbalanced gradient in sodium and potassium, pro-
vide a crucial push into the abysm of cell death for senescent cells.
Our findings contribute to age-related disease drug discovery by
identifying senolytic compounds and demonstrating potential for
therapeutic application.
Methods
Cells and reagents. All cell lines were obtained from the ATCC. Human breast
tumors used to establish Patient-Derived Xenografts (PDXs) in this study were
from biopsies or surgical resections at Vall d’Hebron University Hospital, Barce-
lona, and were obtained following institutional guidelines. The IRBs at Vall
d’Hebron Hospital provided approval in accordance with the Declaration of Hel-
sinki. Written informed consent was obtained from all patients who provided
tissue.
Cells were cultured in DMEM (Sigma) supplemented with 10% FBS (Sigma)
and were routinely tested for mycoplasma contamination. Navitoclax (ABT-263,
Abbvie) was used as standard senolytic reagent. For chemotherapy-induced
senescence we used Bleomycin (Mylan pharmaceuticals) at 20 μM for 5 days.
Alternatively, we also used 1 µM Gemcitabine (Hospira UK), 1 µM Doxorubicine
(TEDEC-MEIJI), 1 µM Etoposide (TEVE Genericos Española), and 5 µM
Palbociclib (Goodchem). For Cardiac Glycosides we used Ouabain (Sigma),
Digoxin (Kern Pharma) and Proscillaridin A (Sigma). Amiloride was from Sigma.
The chemical libraries used for screening were: Prestwick Chemical Library
(Prestwick Chemical), GPNCL library of natural compounds (Greenpharma
Natural Chemical Library), SCREEN-WELL® Natural Product library (ENZO). For
membrane depolarization we used DiBAC4(3) fluorescent probe (Thermofisher),
and pHrodo Green to measure the relative H+concentration.
IC50 calculation. IC50s were calculated using cell cultures induced to senescence
by different stimuli (chemotherapy, RAS expression or exposure to H2O2) and
subsequent treatment with the senolytic compounds starting at a high
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concentration and using serial dilutions of the compounds. Cells were counted
using a High-Content Imaging System (Operetta, Perkin Elmer).
Apoptosis analysis. After treatments, cells were stained for Annexin-V-FITC or
cleaved Caspase-3-PE using commercial kits (Immunostep and BD Biosciences,
respectively) following the protocols from the providers. Positive cells were
determined using FACScalibur (BD Biosciences). To block apoptosis induction, we
used pan-caspase inhibitor Z-VAD-FMK (Santa Cruz Biotechnology) 10 mM for
24 h. In the case of proliferating and g-IR IMR90 cells we used DiOC6(3) to
measure the loss of mitochondrial potential. Cell death was monitored by summing
the % of DioC6(3) low and Hoechst 33342 positive cells.
In vivo senolytic activity. Animal procedures testing senolytic activity on xeno-
grafted A549 cells were approved by University of Santiago de Compostela
Bioethics Committee in compliance with Principles of Laboratory Animal Care of
national laws (license number 15010/17/001). Female 8 weeks old immunodeficient
nude NMRInu/nu mice (Janvier) were subcutaneously injected under isofluorane
anesthesia with 1 × 106 A549-luc cells. When tumors were detectable, mice were
injected intraperitoneally with Gemcitabine (25 mg/Kg; Hospira UK), Digoxin (2
mg/kg; Kern Pharma), or vehicle (PBS), twice weekly. Tumor growth was followed
by measuring their volume using a caliper and the formula V= (W(2) × L)/2, and
by luminescence imaging using IVIS Spectrum in vivo imaging system (Perkin
Elmer). Care and use of animals to test senolysis in human PDX375 at Vall
d’Hebron Campus strictly complied with European, Spanish and Catalan Regula-
tions for Protection of Vertebrate Animals for Experimental and Scientific Pur-
poses. Studies were performed in an authorized establishment (Lab Animal Service
Campus Vall d’Hebron (license number B9900062). Experimental procedure was
essentially identical, with Doxorubicin used as senogenic compound (10 mg/kg).
For the lung fibrosis experiments, protocols were approved by the Ethical Com-
mittee for Animal Experimentation (CEEA) of the Scientific Park of Barcelona
(PCB license number CEEA-19-029) and the Government of Catalunya and
complied with their ethical regulations. Intratracheal administration of 1 × 106
IMR90 cells was followed by Digoxin (2 mg/kg) or vehicle treatment. Lungs were
removed and analyzed by staining for Masson Trichrome or used to extract RNA
for QPCR.
Gene expression. Retroviral or lentiviral transduction was used to overexpress the
following genes: GFP as control (from FUGW, a gift from David Baltimore;
Addgene plasmid #14883)51, HrasV12 (from pBabe-puro-HrasV12, a generous gift
of Matthias Drosten, CNIO, Madrid, Spain); Atp1a1, ATP1A1 and SLC9A1 (a
generous gift from Sean Morrison, UTSW, Dallas, USA)52. To obtain stable A549
cells expressing GFP or RFP for screening, we used pLJM1-EGFP and pLJM3-RFP
(a kind gift from Alejo Efeyan, CNIO, Madrid, Spain). We used the green reporter
vector of System Bioscience (SR010PA-hp21) to follow the expression of the
human CDKN1A. To construct an IL6 reporter we cloned 1.1 kb of the human IL6
promoter into the empty pRZ reporter vector (SR10046), amplified by PCR and
cloned with ClaI and BamHI. For transduction, we co-transfected HEK293T cells
(5 × 106 cells per 100-mm-diameter dish) with the plasmid of interest and the
corresponding packaging vector, the ecotropic pCL-Eco or the third-generation
system: pLP1, pPL2, pLP-VSVG, respectively, using PEI reagent. Viral super-
natants were serially collected 3 times every 12 hours, starting 36 h after trans-
fection. The supernatants were filtered through a 0.45 μm filter and polybrene
(Sigma) was added to a final concentration of 8 μg/mL. The target cells were plated
(1.4 × 106 cells per 100-mm-diameter dish) the day before to the first round of
transduction.
Q-RT-PCR. To measure RNA expression, total RNA was extracted using the
NucleoSpin RNA kit (Macherey-Nagel) according to the manufacturer’s instruc-
tions. After quantification of RNA in a nanodrop, the RNA was retrotranscribed
into cDNA with High-Capacity cDNA-Reverse Transcription Kit (Applied Bio-
systems). Quantitative Real Time-PCR was performed using SYBR Green Power
PCR Master Mix (Applied Biosystems) in an AriaMx Real-Time PCR system
(Agilent Technologies). Relative RNA expression was normalized using the













Senescence-associated β-Galactosidase staining. Senescence-associated β-
Galactosidase (SABG) staining was performed following well-described methods53.
Basically, cells or tissues were fixed at room temperature in 2% formaldehyde/0.2%
glutaraldehyde, washed, and incubated overnight at 37 °C with fresh SABG staining
solution: 1 mg of 5-bromo-4-chloro-3-indolyl beta-D-galactoside (X-Gal) per mL
(Fisher Scientific), 40 mM citric acid/sodium phosphate pH 6.0, 5 mM K3Fe[CN]6,
5 mM K4Fe[CN]6, 150 mM NaCl, and 2 mM MgCl2. Cells were washed and
visualized and photographed under the microscope. Tissues were embedded in
paraffin, sectioned and counterstained with Nuclear Fast Red or further used for
immunohistochemistry.
Immunohistochemical analysis. Whole mount SABG stained tissues were sec-
tioned and slides were incubated overnight at 37 °C before being deparaffinized in
xylene and rehydrated in a descending series of ethanol solutions. Antigen retrieval
was carried out in a PTLink instrument (Dako) and immunoreactive cells were
visualized using 3,3-diaminobenzidine tetrahydrochloride plus (DAB+) as a
chromogen. Sections were incubated with antibodies against proliferative marker
Ki67 (prediluted SP6, Master Diagnostica 0003110QD) and senescence mediator
p21Cip1 (HUGO-291 CNIO, 1:10 dilution).
Statistical analyses. For in vivo studies, mice were randomly assigned to
treatment groups; sample size was not pre-determined. A two-tailed unpaired
Student's t-test was applied for comparison between groups; all analyzed samples
were included for statistical analysis. For some analyses we used Anova with
Tuckey test as indicated. All the experiments were repeated at least three times,
except the in vivo experiment with mice, and a single representative experiment
is shown. All measurements were performed at least in triplicate. Statistical
analyses and graphical representations were performed with GraphPad
Prism 7.0.
More technical details can be found in the Supplementary Methods section
accompanying this paper.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available from the corresponding
authors upon reasonable request. The source data underlying Figs. 1c–f, 2a–c, 3b–i, 4b, c,
e, 5c–f, 6c–f and Supplementary Figs. 1a, b, c, e, f, g, 2, 3a, b, d, e, 4d, and 5a, b are
provided as a Source Data file.
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